USD 1.62
(0.31%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 42.11 Million USD | -22.84% |
2022 | 54.57 Million USD | 12.8% |
2021 | 48.38 Million USD | 15.46% |
2020 | 41.9 Million USD | 67.83% |
2019 | 24.96 Million USD | -36.03% |
2018 | 39.03 Million USD | 286.15% |
2017 | 10.1 Million USD | 89.29% |
2016 | 5.34 Million USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | 42.47 Million USD | 0.86% |
2024 Q2 | 42.86 Million USD | 0.92% |
2023 Q2 | 44.62 Million USD | -14.28% |
2023 Q1 | 52.05 Million USD | -4.61% |
2023 Q3 | 42 Million USD | -5.86% |
2023 Q4 | 42.11 Million USD | 0.25% |
2023 FY | 42.11 Million USD | -22.84% |
2022 Q2 | 61.31 Million USD | 8.59% |
2022 Q1 | 56.47 Million USD | 16.72% |
2022 FY | 54.57 Million USD | 12.8% |
2022 Q4 | 54.57 Million USD | 4.47% |
2022 Q3 | 52.23 Million USD | -14.81% |
2021 Q4 | 48.38 Million USD | 16.58% |
2021 Q3 | 41.5 Million USD | -3.03% |
2021 FY | 48.38 Million USD | 15.46% |
2021 Q1 | 42.62 Million USD | 1.73% |
2021 Q2 | 42.8 Million USD | 0.4% |
2020 Q1 | 34.84 Million USD | 39.57% |
2020 FY | 41.9 Million USD | 67.83% |
2020 Q2 | 41.44 Million USD | 18.92% |
2020 Q3 | 42.74 Million USD | 3.15% |
2020 Q4 | 41.9 Million USD | -1.97% |
2019 Q4 | 24.96 Million USD | 3.29% |
2019 Q3 | 24.17 Million USD | -17.42% |
2019 Q2 | 29.27 Million USD | -6.85% |
2019 Q1 | 31.42 Million USD | -19.5% |
2019 FY | 24.96 Million USD | -36.03% |
2018 FY | 39.03 Million USD | 286.15% |
2018 Q4 | 39.03 Million USD | 24.26% |
2018 Q3 | 31.41 Million USD | 15.5% |
2018 Q2 | 27.19 Million USD | 40.06% |
2018 Q1 | 19.41 Million USD | 92.11% |
2017 Q3 | 5.16 Million USD | 7.67% |
2017 FY | 10.1 Million USD | 89.29% |
2017 Q2 | 4.8 Million USD | 3.45% |
2017 Q1 | 4.64 Million USD | -13.09% |
2017 Q4 | 10.1 Million USD | 95.55% |
2016 Q3 | 1.98 Million USD | -40.13% |
2016 Q2 | 3.31 Million USD | 20.7% |
2016 Q4 | 5.34 Million USD | 169.29% |
2016 FY | 5.34 Million USD | 0.0% |
2016 Q1 | 2.74 Million USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Editas Medicine, Inc. | - USD | -Infinity% |
Dynavax Technologies Corporation | 53.29 Million USD | 20.98% |
Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 45.6% |
Perrigo Company plc | 1.14 Billion USD | 96.309% |
Illumina, Inc. | 587 Million USD | 92.826% |
Thermo Fisher Scientific Inc. | 5.08 Billion USD | 99.172% |
Iovance Biotherapeutics, Inc. | 10.37 Million USD | -305.997% |
Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.494% |
IQVIA Holdings Inc. | - USD | -Infinity% |
Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 98.368% |
Unity Biotechnology, Inc. | - USD | -Infinity% |
Waters Corporation | 516.23 Million USD | 91.843% |
Biogen Inc. | 2.52 Billion USD | 98.334% |
Sangamo Therapeutics, Inc. | - USD | -Infinity% |
Evolus, Inc. | 10.99 Million USD | -282.888% |
Adicet Bio, Inc. | - USD | -Infinity% |
Cara Therapeutics, Inc. | 2.82 Million USD | -1392.733% |
bluebird bio, Inc. | 22.91 Million USD | -83.734% |
Esperion Therapeutics, Inc. | 65.62 Million USD | 35.83% |
FibroGen, Inc. | 41.56 Million USD | -1.311% |
Agilent Technologies, Inc. | 1.03 Billion USD | 95.916% |
Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Homology Medicines, Inc. | - USD | -Infinity% |
Geron Corporation | - USD | -Infinity% |
Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 52.763% |
Amicus Therapeutics, Inc. | 59.69 Million USD | 29.459% |
Myriad Genetics, Inc. | 20.1 Million USD | -109.502% |
Viking Therapeutics, Inc. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | - USD | -Infinity% |
Zoetis Inc. | 2.56 Billion USD | 98.358% |
Abeona Therapeutics Inc. | -2.44 Million USD | 1822.995% |
Mettler-Toledo International Inc. | 385.86 Million USD | 89.087% |
BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 96.197% |
Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 94.3% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -48.144% |
Atara Biotherapeutics, Inc. | 9.7 Million USD | -333.855% |
Verastem, Inc. | - USD | -Infinity% |
Nektar Therapeutics | 16.1 Million USD | -161.537% |
Axsome Therapeutics, Inc. | 15.13 Million USD | -178.229% |
Aclaris Therapeutics, Inc. | - USD | -Infinity% |
Sarepta Therapeutics, Inc. | 322.85 Million USD | 86.957% |
OPKO Health, Inc. | 65.69 Million USD | 35.903% |
Exelixis, Inc. | 17.32 Million USD | -143.087% |
Neurocrine Biosciences, Inc. | 38.3 Million USD | -9.948% |
Corcept Therapeutics Incorporated | 7.73 Million USD | -444.761% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 12.02 Million USD | -250.216% |
Imunon, Inc. | - USD | -Infinity% |
Blueprint Medicines Corporation | 21.22 Million USD | -98.417% |
Insmed Incorporated | 83.24 Million USD | 49.416% |
Halozyme Therapeutics, Inc. | 127.6 Million USD | 66.999% |
Agios Pharmaceuticals, Inc. | 19.07 Million USD | -120.749% |
TG Therapeutics, Inc. | 39.82 Million USD | -5.743% |
Incyte Corporation | 62.97 Million USD | 33.129% |
Emergent BioSolutions Inc. | 328.9 Million USD | 87.197% |